Resource Logo

A bioassay for HIV-1 based on Env-CD4 interaction.


AIDS Res Hum Retroviruses. 1990 Nov;6(11):1281-7. Unique Identifier :

The binding of human immunodeficiency virus type 1 (HIV-1) gp120env to CD4 is the first event leading to infection and represents an important target for possible therapeutic intervention. To provide a tool for screening and quantitation of the effects of drugs inhibiting the Env-CD4 interaction, we developed a simple, fast and quantitative bioassay measuring the fusion between two cell lines generated by stable transfection: one expressing high levels of HIV-1 proteins but no infectious virus (HL2/3), and the other expressing the CD4 receptor and containing an inducible chloramphenicol acetyltransferase (CAT) gene linked to the HIV-1 long terminal repeat (HLCD4-CAT). Upon cocultivation of HL2/3 and HLCD4-CAT cells, efficient cell fusion is observed within 8 h. The efficiency of fusion can be evaluated visually and quantitated by measuring CAT enzyme. This novel bioassay allows testing for drugs capable of interfering with the CD4-Env interaction. HL2/3 cell line secretes gp120env in the medium and can be used for the production of Env protein.

Antigens, CD4/*METABOLISM/PHARMACOLOGY Biological Assay Cell Fusion/DRUG EFFECTS Cell Line Dextran Sulfate/PHARMACOLOGY Giant Cells/CYTOLOGY/DRUG EFFECTS Hela Cells Human HIV Envelope Protein gp120/*METABOLISM HIV Long Terminal Repeat HIV-1/*PHYSIOLOGY Microscopy, Electron Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Transfection JOURNAL ARTICLE


Information in this article was accurate in July 30, 1991. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.